https://www.selleckchem.com/pr....oducts/dabrafenib-gs
53-0.68), indicating weaker predictive power than weight status, and were statistically inferior for nearly all of the comparisons. Despite DXA's high cost and detailed output regarding body composition, its phenotype classification was inferior to weight status in predicting cardiometabolic risk. Further studies investigating the utility of the phenotypes are needed. Despite DXA's high cost and detailed output regarding body composition, its phenotype classification was inferior to weight status in predicting cardiometabo
Synes godt om
Kommentar
Del
